See more : Menicon Co., Ltd. (7780.T) Income Statement Analysis – Financial Results
Complete financial analysis of Vaccinex, Inc. (VCNX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Vaccinex, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Raj Rayon Industries Limited (RAJRILTD.NS) Income Statement Analysis – Financial Results
- Nutrition SC Public Company Limited (NTSC.BK) Income Statement Analysis – Financial Results
- F-star Therapeutics, Inc. (FSTX) Income Statement Analysis – Financial Results
- Northern Star Investment Corp. III (NSTC) Income Statement Analysis – Financial Results
- InsuraGuest Technologies Inc. (ISGIF) Income Statement Analysis – Financial Results
Vaccinex, Inc. (VCNX)
About Vaccinex, Inc.
Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs. The company offers its products for the treatment of cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is pepinemab, a humanized monoclonal antibody that completed and planned Phase 1b/2 clinical trials for the treatment of non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), Huntington's disease, Alzheimer's disease, osteosarcoma, and melanoma. The company is also developing VX5, a human antibody to CXCL13 that is in preclinical development for the treatment of MS and for other autoimmune disorders. Vaccinex, Inc. was incorporated in 2001 and is headquartered in Rochester, New York.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 570.00K | 100.00K | 900.00K | 50.00K | 523.00K | 724.00K | 90.00K | 316.00K |
| Cost of Revenue | 0.00 | 207.00K | 169.00K | 2.00K | 199.00K | 1.03M | 160.00K | 115.00K |
| Gross Profit | 570.00K | -107.00K | 731.00K | 48.00K | 324.00K | -309.00K | -70.00K | 201.00K |
| Gross Profit Ratio | 100.00% | -107.00% | 81.22% | 96.00% | 61.95% | -42.68% | -77.78% | 63.61% |
| Research & Development | 16.57M | 13.98M | 17.16M | 21.55M | 25.67M | 22.35M | 16.55M | 16.03M |
| General & Administrative | 6.88M | 6.20M | 6.23M | 7.41M | 6.67M | 4.62M | 4.48M | 4.43M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 6.88M | 6.20M | 6.23M | 7.41M | 6.67M | 4.62M | 4.48M | 4.43M |
| Other Expenses | 0.00 | -175.00K | 43.00K | -575.00K | 152.00K | 165.00K | -40.00K | -4.00K |
| Operating Expenses | 23.46M | 20.01M | 23.39M | 28.38M | 32.34M | 26.97M | 21.03M | 20.46M |
| Cost & Expenses | 23.46M | 20.01M | 23.39M | 28.38M | 32.54M | 28.01M | 21.19M | 20.58M |
| Interest Income | 0.00 | 2.00K | 809.00K | 489.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 1.00K | 2.00K | 809.00K | 489.00K | 0.00 | 392.00K | 1.36M | 2.99M |
| Depreciation & Amortization | 119.00K | 207.00K | 169.00K | 307.00K | 249.00K | 223.00K | 206.00K | 178.00K |
| EBITDA | -19.75M | -19.61M | -21.40M | -28.06M | -31.61M | -28.90M | -17.20M | -10.78M |
| EBITDA Ratio | -3,464.56% | -19,606.00% | -2,475.33% | -56,110.00% | -6,044.74% | -3,714.50% | -23,264.44% | -6,356.01% |
| Operating Income | -22.89M | -19.91M | -22.49M | -28.33M | -32.02M | -27.28M | -21.10M | -20.26M |
| Operating Income Ratio | -4,014.91% | -19,906.00% | -2,498.89% | -56,662.00% | -6,121.41% | -3,768.09% | -23,448.89% | -6,411.08% |
| Total Other Income/Expenses | 2.63M | 91.00K | 110.00K | -520.00K | 152.00K | -2.24M | 2.35M | 6.32M |
| Income Before Tax | -20.25M | -19.82M | -22.38M | -28.85M | -31.86M | -29.52M | -18.76M | -13.94M |
| Income Before Tax Ratio | -3,552.81% | -19,815.00% | -2,486.67% | -57,702.00% | -6,092.35% | -4,077.07% | -20,843.33% | -4,412.34% |
| Income Tax Expense | 0.00 | -93.00K | 852.00K | 458.00K | 152.00K | -1.85M | 1.28M | 2.99M |
| Net Income | -20.25M | -19.72M | -23.23M | -29.31M | -32.02M | -29.52M | -18.72M | -13.94M |
| Net Income Ratio | -3,552.81% | -19,722.00% | -2,581.33% | -58,618.00% | -6,121.41% | -4,077.07% | -20,802.22% | -4,412.34% |
| EPS | -43.68 | -97.59 | -170.04 | -327.62 | -521.95 | -1.19K | -689.86 | -526.85 |
| EPS Diluted | -43.68 | -97.59 | -169.11 | -327.62 | -521.95 | -1.19K | -689.86 | -526.85 |
| Weighted Avg Shares Out | 463.65K | 202.08K | 136.63K | 89.46K | 61.34K | 24.87K | 27.14K | 26.47K |
| Weighted Avg Shares Out (Dil) | 463.65K | 202.08K | 137.38K | 89.46K | 61.34K | 24.87K | 27.14K | 26.47K |
Why Vaccinex Shares Are Rallying
VCNX Stock Price Increases Over 60% Pre-Market: Why It Happened
Vaccinex Rallies After Announcing Multi-Project Pact Using Its Antibody Discovery Platform
Vaccinex Announces Signing of Two Multi-Project Deals with Leading Pharmaceutical Companies Focused on Leveraging Its ActivMAb® Platform
Bet on Rising P/E With These 5 Top-Ranked Stocks
Vaccinex to Participate in the LifeSci Partners 10th Annual Healthcare Corporate Access Event
Vaccinex Reports Third Quarter 2020 Financial Results and Provides Corporate Update
CORRECTION -- Vaccinex to Present Additional SIGNAL Data at Huntington Study Group 2020 Medical Conference
Vaccinex to Present Additional SIGNAL Data at Huntington Study Group 2020 Medical Conference
Source: https://incomestatements.info
Category: Stock Reports